Ironwood Pharmaceuticals (IRWD) Net Cash Flow (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Net Cash Flow across 17 years of filings, most recently posting $5.1 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $5.1 million, down 74.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $112.4 million (up 965.02% YoY), and the FY2025 annual result was $127.2 million, up 3670.75% from the prior year.
• Net Cash Flow came in at $5.1 million for Q1 2026 at Ironwood Pharmaceuticals, down from $74.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $84.1 million in Q1 2023 to a low of -$565.5 million in Q2 2023.
• The 5-year median for Net Cash Flow is $327000.0 (2024), against an average of -$23.6 million.
• Across the five-year window, Net Cash Flow tumbled 535.3% in 2023 and surged 22743.43% in 2025, its largest moves.
• Ironwood Pharmaceuticals' Net Cash Flow stood at $82.0 million in 2022, then tumbled by 123.48% to -$19.3 million in 2023, then surged by 101.7% to $327000.0 in 2024, then soared by 22743.43% to $74.7 million in 2025, then sank by 93.14% to $5.1 million in 2026.
• The last three Net Cash Flow figures came in at $5.1 million (Q1 2026), $74.7 million (Q4 2025), and $47.6 million (Q3 2025), per Business Quant data.